82.1% initially diagnosed at stage IV. Common sites of metastasis were bone (41.1%), brain (23.2%), contralateral lung (19.0%), and liver (15.8%). 24.2% were current smokers; 67.4% past (median 38 pack years). There were no differences in these characteristics by regimen. The most common comorbidities were COPD (30.5%) and diabetes (16.8%). Most patients were from the South (56.8%) vs. Northeast (13.7%), Midwest (21.1%), and West (8.4%). Patients from the South were 3 times as likely (OR = 3.02) to receive a bevacizumab-containing regimen (Regimens B+D) than patients from the non-South regions, χ 2 = 6.5293, df = 1, p = 0.0106. ConClusions: Patients treated for advanced NSCLC in real world settings appear demographically and clinically similar to patients treated in clinical trials. Preliminary findings suggest regional differences in chemotherapeutic treatment patterns.
objeCtives: There has been an increasing concern about the link between statins and the risk for cataract. This study detects and clarifies signals of cataract formation and operation associated with lipid-lowering drugs (LLD), including statins, from postmarketing adverse event reports. Methods: A pharmacovigilance analysis of adverse events submitted to the FDA Adverse Event Reporting System between Oct1997 and Sep2012 was conducted. Multi-item Gamma Poisson Shrinker algorithm was applied to detect signals of cataract and cataract operation. Empirical Bayes Geometric Mean (EBGM) and corresponding 95%CI (EB05-EB95) were estimated for drug-event combinations of interest. Estimates with EB05≥ 2 are significant disproportional reporting of the event for LLD. The MedDRA Preferred Term hierarchy was used to define events, and generic name of the reported drug was used to define LLD exposure. Results: 1,195 cataract and 99 cataract operation reports were submitted for LLD (respectively, 94% and 95% of these reports were for statins). Most of cataract reports were for lovastatin (n= 399) and most of cataract operation reports were for atorvastatin (n= 68). Among LLD, cataract signal was detected for statins (EBGM 3.64, EB05-EB95 3.18-4.2). Among statins, lovastatin was associated with the strongest signal for cataract formation (EBGM 12.8, , followed by pravastatin (EBGM 3.82, EB05-EB95 3.21-4.53) and atorvastatin (EBGM 2.95, EB05-EB95 2.7-3.21). No cataract operation signal was detected for any LLD class, including statins (EBGM 1.52, EB05-EB95 1.08-2.36); however, cataract operation signals were detected for rosuvastatin (EBGM 3.82, EB05-EB95 3.21-4.53) and atorvastatin (EBGM 3.33, EB95-EB95 2.72-4.05). Disproportional reporting of cataract with EB05> 1 was found for simvastatin (EB05= 1.66), fluvastatin (EB05= 1.34) and gemfibrozil (EB05= 1.32). ConClusions: Antilipemic treatment with statins may be associated with an increased risk of cataract development or operation. Statin users with risk factors for cataract formation should have routine ophthalmic examination for lenticular opacity, and alternative LLD should be used in high-risk individuals. objeCtives: During the last decade, the standard of care to treat acute coronary syndrome (ACS) patients was typically a combination of clopidogrel and aspirin. However, newer antiplatelet agents were approved recently. The aim of this study was to assess the effect on time-to-readmission and resource utilization of prasugrel vs. clopidogrel in prasugrel treated patients after hospitalization with an ACS event. Methods: Based on the Truven Health Analytics MarketScan database from January 2009 through July 2012 a matched-cohort was created. Inferences for average treatment effect on time-to-readmission and numbers of hospitalizations, ER visits, and outpatient visits in prasugrel treated patients at 30 days and 1 year were performed by (1) frequentist Kaplan-Meier estimation with a log-rank test and Lin's method for censored resource utilization outcomes; and (2) Bayesian discrete-time hazard models and negative binomial models. Bayes factors were also determined. Results: 10,963 matched-pairs were well-balanced on baseline characteristics. Frequentist analyses of time-to-readmission at 1 year and resource utilization rates over 30 and 365 days showed no statistical differences between prasugrel and clopidogrel (log-rank test and Lin method p-values all > 0.05 ). The posterior probability of equivalence between drugs for time-to-readmission at a margin of 10% was 98.7%, and based on the Bayes factor for superiority there is little evidence of superiority. Based on Bayesian analyses of resource utilization outcomes there are high probabilities of equivalence at a margin of 10% and little evidence of superiority for all outcomes except for number of hospitalizations at 30 days, for which there is positive evidence that clopidogrel is superior to prasugrel, although the probability that prasugrel is non-inferior to clopidogrel at the 10% margin is 0.765. ConClusions: ACS patients treated with prasugrel had time-toreadmission and resource utilization outcomes equivalent to what they would have been if treated with clopidogrel.
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COMPLICATIOnS RELATED TO CARDIAC RhyThM MAnAgEMEnT DEVICES (CRMD'S) ThERAPy AnD ThEIR fInAnCIAL IMPLICATIOn:A PROSPECTIVE SIngLE-CEnTER TwO yEARS SURVEy
Fanourgiakis J. , Simantirakis E. , Kanoupakis E. , Chrysostomakis S. , Chlouverakis G. , Vardas P. University of Crete, Heraklion, Greece objeCtives: Cardiac rhythm management devices (CRMD's) have proven their clinical effectiveness for patients with heart rhythm disorders. Little is known about safety and complication rates during implantations of these devices. This study demonstrated the complications rates related to implantations of CRMD's, and estimated the additional hospital stay and cost associated with managing these complications. Methods: During a period of one year in total 464 consecutive recipients were subjected to CRMD's implantation and furthermore were recruited and followed up for 2 years. Finally, data were analyzed for 398 patients who completed the two year's follow up, resulting in a total of 796 patient-years. Results: From the 201 patients with initial pacemaker (PM) implantations, 6 (2,99 %) patients had seven complications (5 patients had lead's dislodgement, 1 of them twice and 1 patient developed pocket infection), while from the 117 PMs replacements 1 (0,85 %) patient developed a complication (pocket erosion). 2 patients with complication (1 with an initial PM and 1 with replacement) died before they complete the follow up from reasons unrelated to cardiac causes. There weren't any complications neither in initial implantations (69 patients) nor in replacements (11 patients) of implantable cardioverter defibrillator (ICD). The average prolongation of the hospital stay was 7 days ranging from 1 to 35 days, resulting in 17.411 € of total additional direct hospital cost. ConClusions: This study provides relatively low rates of complications in patients subjected to PMs implantation, initial or replacement, in our center compared with others studies. In the case of ICD implantations, initials or replacements, there weren't any complication. The additional hospitalization days and cost attributed to these complications depends on the nature of complication. Groupe d'analyse, Ltée, Montréal, QC, Canada, 2 Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 3 Janssen Scientific Affairs, LLC, NJ, USA objeCtives: Unlike rivaroxaban, warfarin requires laboratory monitoring to document achievement of international normalized ratio goal, thereby potentially prolonging a patient's hospital length of stay (LOS). The study objective was to compare hospital LOS among hospitalized non-valvular atrial fibrillation (NVAF) patients using rivaroxaban versus warfarin in a real-world setting. Methods: A retrospective claims analysis was conducted using the Premier Perspective Comparative Hospital Database from 11/2010 to 9/2012. Adult patients were included in the study if they had an index hospitalization for NVAF. Patients initiating rivaroxaban during hospitalization were matched with up to 4 warfarin users by propensity score analyses. Similar matched sub-analyses were conducted for patients who (1) had pre-treatment use of parenteral anticoagulants, and (2) were administered their oral anticoagulants on day 3 of their hospital stay or later. Comparison of hospital LOS was assessed using generalized estimating equations. Results: The characteristics of the matched cohorts were well balanced. Among the matched rivaroxaban and warfarin users (2,809 and 11,085 patients, respectively), the mean age of the cohorts was 71 years and 49% were females. The average [median] hospital LOS for rivaroxaban patients was 4.5 [3] days compared to 5.3 [4] days for the warfarin cohort. The mean difference in hospital LOS of 0.81 days was found to be significant at p< 0.01. In the sub-analyses of patients with pre-treatment use of parenteral anticoagulants, the average hospital LOS was found to be 1.38 days shorter (p< 0.01) for the rivaroxaban group as compared to the warfarin group. Patients who were administered rivaroxaban on day 3 of their hospital stay or later had a 1.72 day shorter LOS as compared to their matched warfarin counterparts (p< 0.01). ConClusions: This study suggests that NVAF patients receiving rivaroxaban have significantly lower hospital length of stay as compared to patients receiving warfarin. Groupe d'analyse, Ltée, Montréal, QC, Canada, 2 Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 3 University of Connecticut, Storrs, CT, USA, 4 Janssen Scientific Affairs, LLC, NJ, USA, 5 Janssen Research and Development, LLC, Raritan, NJ, USA objeCtives: Rivaroxaban was shown to be effective in reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF) in a randomized controlled trial setting. The study objective was to assess real-world safety, effectiveness, and persistence of rivaroxaban and warfarin in nonvalvular AF patients. Methods: Health care claims from Symphony Health Solutions' Patient Transactional Datasets from 5/2011-7/2012 were analyzed. Adult patients newly initiated on rivaroxaban or warfarin, with ≥ 2 AF diagnoses (ICD-9-CM: 427.31), and a CHADS2 score ≥ 1 during the 180-day baseline period were included. Cohorts were matched 1:4 using propensity score methods. Study outcomes were major bleeding, intracranial hemorrhage (ICH), gastrointestinal (GI) bleeding, composite stroke and systemic embolism, and venous thromboembolism (VTE) events (deep vein thrombosis [DVT] and pulmonary embolism [PE] ). Cox proportional hazard models were used to compare event and persistence rates. Results: The matched sample included 3,654 rivaroxaban and 14,616 warfarin patients. Matching was adequate, with all standardized differences in patient characteristics < 10%. Mean age of both cohorts was 73 years; 51% were female. The mean (SD) drug exposure for the rivaroxaban and warfarin cohorts was 83 (58.0) and 114 (70.2) days, respectively. No significant differences were observed for bleeding, and the composite stroke and systemic embolism outcomes, although rivaroxaban users were associated with significantly fewer VTE events (hazard ratio [HR] = 0.46, 95% confidence interval [CI]: 0.23-0.91, p= 0.0250) compared to warfarin users. Rivaroxaban was also associated with a significantly lower risk of treatment non-persistence (HR= 0.66; 95%CI: 0.60-0.72, p< 0.001). ConClusions: This analysis suggests that rivaroxaban
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